Compare QUALCOMM, Inc. (QCOM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs 10X Genomics Inc — how do they compare? QUALCOMM, Inc. trades at $176.72 (market cap $182.87B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: QUALCOMM, Inc. is far larger — about 33.4× 10X Genomics Inc's market cap, and QUALCOMM, Inc. pays a 2.12% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| QCOM | TXG | |
|---|---|---|
Market Cap | $182.87B | $5.48B |
Sector | Technology | Health |
52-Week High | $251.10 | $47.20 |
52-Week Low | $124.07 | $11.34 |
Enterprise Value | $188.34B | $5.02B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $175.55, up 3.07% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 22.31% net income margin and 29.27% ROE, though margins face pressure. Analyst consensus is a $228.22 price target with 42.65% buy ratings. Recent news highlights AI and data center growth initiatives amid smartphone market challenges.
The outlook balances AI diversification potential against near-term margin and competitive risks. Investment opportunity lies in data center revenue growth and market share gains, but risks include Nvidia's PC chip entry and handset demand softness. Wall Street remains cautiously optimistic with a hold-heavy rating distribution.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
